Combined proteomics/miRNomics of dendritic cell immunotherapy-treated glioblastoma patients as a screening for survival-associated factors.
CNS cancer
Cancer therapy
Cell vaccines
Translational research
Tumour immunology
Journal
NPJ vaccines
ISSN: 2059-0105
Titre abrégé: NPJ Vaccines
Pays: England
ID NLM: 101699863
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
07
2019
accepted:
25
11
2019
entrez:
24
1
2020
pubmed:
24
1
2020
medline:
24
1
2020
Statut:
epublish
Résumé
Glioblastoma is the most prevalent and aggressive brain cancer. With a median overall survival of ~15-20 months under standard therapy, novel treatment approaches are desperately needed. A recent phase II clinical trial with a personalized immunotherapy based on tumor lysate-charged dendritic cell (DC) vaccination, however, failed to prolong survival. Here, we investigated tumor tissue from trial patients to explore glioblastoma survival-related factors. We followed an innovative approach of combining mass spectrometry-based quantitative proteomics (
Identifiants
pubmed: 31969991
doi: 10.1038/s41541-019-0149-x
pii: 149
pmc: PMC6965118
doi:
Types de publication
Journal Article
Langues
eng
Pagination
5Informations de copyright
© The Author(s) 2020.
Déclaration de conflit d'intérêts
Competing interestsC.V., S.K., K.F. and R.R. were employees of Activartis Biotech GmbH at the time of this investigation. F.E. and A.M.D. were formerly (part‐time) employees of Activartis Biotech GmbH. The authors declare that the research was conducted in the absence of any other commercial, financial or personal relationships that could be construed as a potential competing interest.
Références
J Med Chem. 2008 Dec 11;51(23):7405-16
pubmed: 18989950
J Cell Mol Med. 2019 Jan;23(1):281-292
pubmed: 30467961
Clin Cancer Res. 2005 Aug 1;11(15):5515-25
pubmed: 16061868
Neuro Oncol. 2013 Mar;15(3):319-29
pubmed: 23328812
Adv Exp Med Biol. 2013;986:171-87
pubmed: 22879069
PLoS One. 2014 Sep 29;9(9):e108171
pubmed: 25265448
Sci Transl Med. 2017 Jul 19;9(399):
pubmed: 28724573
Clin Cancer Res. 2010 May 15;16(10):2715-28
pubmed: 20442299
Nat Rev Cancer. 2015 Jun;15(6):321-33
pubmed: 25998712
Mol Cell Proteomics. 2017 Sep;16(9):1563-1577
pubmed: 28637836
Nat Cell Biol. 2008 Dec;10(12):1470-6
pubmed: 19011622
Bone. 2015 Oct;79:43-51
pubmed: 26026730
Cancer Invest. 2012 Jan;30(1):48-56
pubmed: 22236189
Cancer Res. 2004 Jul 15;64(14):4973-9
pubmed: 15256471
Oncotarget. 2015 Sep 8;6(26):22526-52
pubmed: 26188123
Biochem Pharmacol. 2013 Feb 15;85(4):478-85
pubmed: 23159669
Nat Rev Clin Oncol. 2018 Jul;15(7):422-442
pubmed: 29643471
Front Biosci (Landmark Ed). 2014 Jan 01;19:687-706
pubmed: 24389213
Front Immunol. 2018 May 29;9:727
pubmed: 29910795
PLoS One. 2013 Apr 16;8(4):e61801
pubmed: 23613942
Cancer Cell. 2006 May;9(5):391-403
pubmed: 16697959
Clin Cancer Res. 2011 Mar 15;17(6):1603-15
pubmed: 21135147
Nucleic Acids Res. 2015 Jan;43(Database issue):D447-52
pubmed: 25352553
Am J Cancer Res. 2015 Feb 15;5(3):945-55
pubmed: 26045979
Nucleic Acids Res. 2017 Jan 4;45(D1):D1100-D1106
pubmed: 27924013
N Engl J Med. 2001 Jan 11;344(2):114-23
pubmed: 11150363
PLoS One. 2012;7(4):e35596
pubmed: 22530056
Funct Integr Genomics. 2017 May;17(2-3):203-212
pubmed: 27541609
J Immunother Cancer. 2018 Jan 23;6(1):8
pubmed: 29357948
Oncol Rep. 2015 Apr;33(4):2009-16
pubmed: 25625667
Cancer Res. 2008 Jul 15;68(14):5955-64
pubmed: 18632651
Acta Neuropathol Commun. 2018 Dec 5;6(1):135
pubmed: 30518425
Nat Med. 2016 Aug;22(8):851-60
pubmed: 27376576
Cancer Cell. 2015 Oct 12;28(4):441-455
pubmed: 26461092
Nat Rev Neurol. 2019 Jun;15(6):314-315
pubmed: 30936570
J Clin Oncol. 2016 May 10;34(14):1611-9
pubmed: 26976423
Sci Rep. 2017 Mar 03;7:43605
pubmed: 28256619
Ann Oncol. 2016 Dec;27(12):2268-2274
pubmed: 27733373
J Neurooncol. 2017 Jan;131(1):1-9
pubmed: 27743144
J Transl Med. 2018 May 29;16(1):142
pubmed: 29843811
Nature. 2015 Dec 3;528(7580):93-8
pubmed: 26536111
Nature. 2014 Aug 21;512(7514):324-7
pubmed: 25043048
Science. 2013 Dec 20;342(6165):1432-3
pubmed: 24357284
BMC Bioinformatics. 2012;13 Suppl 16:S12
pubmed: 23176165
Genome Res. 2003 Nov;13(11):2498-504
pubmed: 14597658
Nat Rev Immunol. 2010 Feb;10(2):111-22
pubmed: 20098459
Cancer Immunol Immunother. 2013 Jan;62(1):125-35
pubmed: 22847020
Cell Oncol (Dordr). 2016 Jun;39(3):229-42
pubmed: 26883759
Exp Mol Med. 2010 Apr 30;42(4):233-44
pubmed: 20177143
Neuro Oncol. 2010 May;12(5):422-33
pubmed: 20406893
Cancer Res. 2006 Nov 1;66(21):10247-52
pubmed: 17079441
J Immunother Cancer. 2014 May 13;2:10
pubmed: 24883189
Cancer Cell. 2010 Dec 14;18(6):655-68
pubmed: 21156287
Cancers (Basel). 2018 Oct 05;10(10):
pubmed: 30301187
J Cell Sci. 2011 Sep 1;124(Pt 17):2997-3005
pubmed: 21878506
Nat Commun. 2016 Feb 22;7:10743
pubmed: 26899176
Nat Rev Cancer. 2014 Sep;14(9):598-610
pubmed: 25098269
Oncogene. 2012 Jul 5;31(27):3235-43
pubmed: 22056879
J Neurooncol. 2007 Jun;83(2):121-31
pubmed: 17077937
Br J Cancer. 2011 Feb 1;104(3):448-59
pubmed: 21224854
Eur J Neurosci. 2014 Dec;40(11):3573-90
pubmed: 25263991
Nucleic Acids Res. 2017 Jan 4;45(D1):D362-D368
pubmed: 27924014
Lancet Oncol. 2017 Oct;18(10):1373-1385
pubmed: 28844499
Science. 2017 Dec 1;358(6367):
pubmed: 29191878
Cell. 2015 Sep 24;163(1):160-73
pubmed: 26406376
Mol Cancer Ther. 2013 Feb;12(2):162-72
pubmed: 23243059
PLoS One. 2013;8(1):e52875
pubmed: 23341914
N Engl J Med. 2005 Mar 10;352(10):987-96
pubmed: 15758009
Cell Stem Cell. 2009 Nov 6;5(5):504-14
pubmed: 19896441
Br J Cancer. 2008 Dec 16;99(12):2044-53
pubmed: 19018263
Clin Cancer Res. 2010 Apr 15;16(8):2443-9
pubmed: 20371685
Mol Oncol. 2014 Sep 12;8(6):1132-9
pubmed: 25106088